For a 61‑kg adult with type 1 diabetes on insulin glargine (Lantus) 10 U basal and rapid‑acting insulin for meals and a 2 am snack, with consistently elevated glucose readings, how can I modestly tighten the carbohydrate‑to‑insulin ratios, insulin‑sensitivity factor, and basal insulin while preventing insulin stacking, given concerns that the patient may be hoarding food and I want to avoid a large increase in the carbohydrate ratio?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: June 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Addressing Insulin Stacking and Behavioral Food Hoarding in Type 1 Diabetes

Given your concern about behavioral food hoarding at 2 AM, focus on tightening the insulin sensitivity factor (correction factor) first rather than aggressively increasing the carbohydrate ratio, and consider reducing or eliminating the scheduled 2 AM snack entirely while optimizing basal insulin coverage for that time period.

Strategic Approach to Dose Adjustments

1. Prioritize Basal Insulin Optimization

Your patient is on only 10 units of glargine for a 61-kg adult, which calculates to approximately 0.16 units/kg—at the lower end of typical dosing. Research suggests that optimal basal dosing is typically 0.2 units/kg (approximately 12 units for this patient) 1. Increase the basal glargine by 2 units every 3 days until fasting glucose reaches target without hypoglycemia 2.

  • The current basal dose may be insufficient, leading to compensatory over-bolusing at meals
  • A stronger basal foundation reduces the temptation to "stack" rapid-acting insulin
  • Monitor continuous glucose patterns from 2 AM to 6 AM specifically to assess overnight coverage

2. Tighten the Correction Factor Before the Carb Ratio

The correction factor (insulin sensitivity factor) directly addresses hyperglycemia without requiring accurate carbohydrate counting—critical when food hoarding is suspected.

Use the formula: CF = 90/TBD 1. If total basal dose increases to 12 units, the correction factor should be approximately 90/12 = 7.5 (meaning 1 unit lowers glucose by ~7.5 mg/dL or ~0.4 mmol/L).

  • Tightening the correction factor addresses the elevated readings without requiring the patient to accurately report carbohydrate intake
  • This prevents insulin stacking because corrections are calculated based on actual glucose readings, not estimated food
  • Adjust by 10-15% increments 2

3. Modest Carbohydrate Ratio Adjustment

Use the relationship: ICR = CF/4.5 1. If your new correction factor is 7.5, the insulin-to-carbohydrate ratio should be approximately 1:17 (1 unit per 17 grams of carbohydrate).

  • Adjust the carb ratio by only 1-2 grams at a time for the meals showing consistent post-meal hyperglycemia
  • Avoid aggressive changes that might encourage the patient to under-report food intake
  • Research demonstrates that reducing basal insulin while compensatorily increasing meal insulin (when appropriate) can improve control without weight gain or increased hypoglycemia 3

4. Address the 2 AM Snack Behaviorally

Eliminate the scheduled 2 AM snack if it's not medically necessary for hypoglycemia prevention. The FDA labeling for Lantus emphasizes once-daily dosing at the same time each day with stable 24-hour coverage 4.

  • If the patient truly needs overnight coverage, optimize the basal insulin instead of relying on a scheduled snack
  • A properly dosed basal insulin should maintain euglycemia for 24 hours without requiring food intake 4
  • If the patient is waking to eat due to nocturnal hypoglycemia, this suggests basal insulin is too high or mistimed—not that more food is needed

5. Prevent Insulin Stacking with Clear Timing Rules

Establish a minimum 3-4 hour interval between rapid-acting insulin doses and educate the patient that correction doses should not be given within 3 hours of the previous bolus.

  • Most rapid-acting insulins have a duration of action of 3-5 hours
  • The FDA labeling emphasizes that mixing or improper timing can lead to severe hypoglycemia 4
  • Consider using insulin-on-board calculations if the patient uses a pump or smart pen

Critical Pitfalls to Avoid

  • Don't aggressively increase carb ratios when food intake is unreliable: This creates a dangerous situation where underreported food leads to inadequate insulin coverage
  • Don't ignore the basal-to-bolus ratio: Research shows that many patients are "overbasalized" with inadequate meal coverage 2. Your patient may be the opposite—underbasal with excessive corrections
  • Don't continue scheduled snacks that enable behavioral patterns: If the 2 AM eating is truly behavioral, providing insulin for it medicalizes and perpetuates the behavior

Monitoring Strategy

  • Increase frequency of glucose monitoring, especially 2-4 hours post-meal and overnight (2 AM-6 AM)
  • Look for patterns suggesting the basal insulin is insufficient (rising glucose overnight even without food)
  • Assess for hypoglycemia that might be driving compensatory overeating: if present, reduce insulin by 10-20% 2

The key principle: Build a solid basal foundation first (targeting 0.2 units/kg), then fine-tune correction factors to address hyperglycemia independent of reported food intake, and only modestly adjust carb ratios when you have confidence in the patient's carbohydrate reporting.

References

1
Research

How much do I give? Dose estimation formulas for once-nightly insulin glargine and premeal insulin lispro in type 1 diabetes mellitus.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists, 2012

Related Questions

How should I adjust the insulin regimen for a patient with elevated pre‑lunch and pre‑dinner blood glucose who is currently taking insulin lispro 25 U before breakfast, 2 U before lunch, 6 U before dinner, and insulin glargine (Lantus) 16 U at bedtime?
For a patient with type 1 diabetes currently on insulin glargine (Lantus) 18 U daily, daytime insulin‑sensitivity factor of 25 mg/dL per unit, overnight factor of 50 mg/dL per unit, and insulin‑to‑carbohydrate ratio of 1 U per 8 g, who ate 56 g carbohydrate at 14:00 with a blood glucose of 200 mg/dL at 16:00, then ate 82 g carbohydrate at 19:00 with a blood glucose of 199 mg/dL at 22:00, and had a blood glucose of 132 mg/dL at 04:00, what should the insulin glargine dose, insulin‑sensitivity factor, and insulin‑to‑carbohydrate ratio be adjusted to?
In a diabetic patient taking Lantus (insulin glargine) 24 units each evening with persistently elevated glucose levels, how should the regimen be adjusted?
For a patient on insulin glargine (Lantus) 18 units with an insulin‑sensitivity factor of 25 mg/dL per unit and an insulin‑to‑carbohydrate ratio of 10 g per unit, who has blood glucose readings of 234 mg/dL at 5 PM after eating 66 g of carbohydrate, 240 mg/dL at 9 PM, and 201 mg/dL at 2 AM, what should the insulin‑sensitivity factor, insulin‑to‑carbohydrate ratio, and basal Lantus dose be adjusted to?
Why might insulin glargine (Lantus) cause an increase in blood glucose?
What is the difference between hyoscine (scopolamine) base and hyoscine butylbromide (Buscopan) in terms of central nervous system penetration and anti‑emetic effects?
What is the appropriate management of a complex fibroadenoma?
Can azathioprine cause macrocytosis?
What are the effects of applying triamcinolone cream as a lotion instead of a thin layer?
At what blood pressure threshold should antihypertensive therapy with lisinopril (angiotensin‑converting enzyme inhibitor) and hydrochlorothiazide (thiazide diuretic) be held or discontinued in a patient whose current reading is 107/76 mm Hg?
What punch biopsy size is recommended for sampling the skin or superficial nipple‑areolar lesion in a patient with suspected breast carcinoma?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.